Skip to content

Glaukos GKOS Change in AP

Change in AP at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$3.92B-84.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$107.7M+150%
AbbVie logo
AbbVieABBV
-$1.59B-129%
Boston Scientific logo
Boston ScientificBSX
-$512M-33.0%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$2M-14.0%
Exelixis logo
ExelixisEXEL
-$17.9M-311%

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's change in AP?
Glaukos (GKOS) reported change in AP of -$10.19M in Q1 2026.
How has Glaukos's change in AP changed year-over-year?
Glaukos's change in AP decreased by 51.5% year-over-year, from -$6.73M to -$10.19M.
What is the long-term trend for Glaukos's change in AP?
Over 3 years (2022 to 2025), Glaukos's change in AP has grown at a 37.7% compound annual growth rate (CAGR), from $7.21M to $18.82M.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.